CNS involvement in MCL
| Study . | Patients with CNS involvement/ total no. of patients . | Median time to CNS disease, mo . | No. of patients with blastoid morphology . | No. of patients with involvement at diagnosis . | First-line treatment with CNS-penetrating agents . | Prophylaxis with intrathecal chemotherapy . |
|---|---|---|---|---|---|---|
| Oinonen et al6 | 4/94 (5%) | 51 | 1 | 0 | Some (unknown) | Unknown |
| Valdez et al5 | 25/108 (23%) | 15.5 | 2 | 1 | Unknown | 0 |
| Ferrer et al3 | 11/82 (13%) | 25 | 5 | 1 | 20% | 0 |
| Gill et al4 | 4/62 (6.5%) | 12 | 2 | 1 | 16% | 10% |
| Study . | Patients with CNS involvement/ total no. of patients . | Median time to CNS disease, mo . | No. of patients with blastoid morphology . | No. of patients with involvement at diagnosis . | First-line treatment with CNS-penetrating agents . | Prophylaxis with intrathecal chemotherapy . |
|---|---|---|---|---|---|---|
| Oinonen et al6 | 4/94 (5%) | 51 | 1 | 0 | Some (unknown) | Unknown |
| Valdez et al5 | 25/108 (23%) | 15.5 | 2 | 1 | Unknown | 0 |
| Ferrer et al3 | 11/82 (13%) | 25 | 5 | 1 | 20% | 0 |
| Gill et al4 | 4/62 (6.5%) | 12 | 2 | 1 | 16% | 10% |